The Medical Developments International Ltd (ASX: MVP) share price has charged higher this morning following the release of a positive announcement.
At the time of writing the healthcare company’s shares are up almost 4% to $5.29.
What was announced?
This morning Medical Developments International announced that it has reached an agreement with Mundipharma for the exclusive distribution rights of its key Penthrox pain management product in Australia.
According to the release, the agreement will see Mundipharma provide its salesforce and marketing experience, whereas Medical Developments International will continue to maintain relationships within the key ambulance channel and support Mundipharma with their marketing endeavours.
The agreement contains minimum volumes which guarantee current turnover in Australia but with significant forecast upside.
Medical Developments International’s CEO, John Sharman, believes this is a great deal for the company.
He said: “This is an exciting deal for MVP because Mundipharma has a respected presence in the pain market with broad sales force coverage across Australia. This presence in the field is expected to lead to impressive sales growth in the short to medium term, particularly within General Practitioner and Hospital channels.”
Mundipharma Australia and New Zealand’s managing director, Jane Orr, was equally pleased with the deal.
She said: “Options for pain relief are limited in many clinical settings, particularly GP procedure rooms, so we welcome the opportunity to help address this important clinical need. Mundipharma has provided medicines for the management of pain and worked collaboratively with healthcare professionals to provide education on pain management for more than 20 years in Australia, so Penthrox is an ideal fit for our business.”
Finally, Medical Developments International’s chairman, David Williams, revealed that the company hopes this deal shows “international distributors the upside that is possible with a strong sales force.”
Elsewhere in the healthcare sector on Monday, the Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has dropped lower after the U.S. FDA delayed its PDUFA date for its SCENESSE product and the Starpharma Holdings Limited (ASX: SPL) share price is higher after signing a second oncology agreement with AstraZeneca.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Medical Developments International Limited and Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.